In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.31 below Urogen Pharma Ltd average.

Within Major Pharmaceutical Preparations industry 299 other companies have achieved higher Quick Ratio than Urogen Pharma Ltd in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 636 to 1504.

Explain Quick Ratio?
How much Cash & cash equivalents URGN�s has?
What are URGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

URGN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	60.78 %	20.58 %	15.14 %	0.63 %	27.95 %
Y / Y Cash & cash equivalent Change	7.59 %	16.23 %	5.69 %	-6.96 %	-28.04 %
Quick Ratio MRQ	1.31	1.74	2.09	3.32	1.96
URGN's Total Ranking	# 1504	# 636	# 720	# 637	#
Seq. Current Liabilities Change	19.57 %	17.41 %	9.35 %	4.74 %	-10.33 %
Seq. Cash & cash equivalent Change	-10.28 %	-1.8 %	-31.3 %	77.73 %	-3.07 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 300
Healthcare Sector	# 525
Overall Market	# 1504

Quick Ratio Statistics
High	Average	Low
24.04	5.24	0.68
(Mar 31 2019)		(Jun 30 2023)

Financial Statements
Urogen Pharma Ltd 's Current Liabilities	$ 74 Millions	Visit URGN's Balance sheet
Urogen Pharma Ltd 's Cash & cash equivalent	$ 97 Millions	Visit URGN's Balance sheet
Source of URGN's Sales		Visit URGN's Sales by Geography

Cumulative Urogen Pharma Ltd 's Quick Ratio

URGN's Quick Ratio for the trailling 12 Months

URGN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	23.96 %	15.39 %	18.68 %	26.87 %	40.39 %
Y / Y Cash & cash equivalent TTM Growth	3.45 %	-5.28 %	-27.08 %	-31.07 %	-19.69 %
Quick Ratio TTM	2	2.24	2.28	2.34	2.4
Total Ranking TTM	# 695	# 769	# 481	# 410	# 304
Seq. Current Liabilities TTM Growth	13.4 %	5.33 %	3.62 %	0.16 %	5.55 %
Seq. Cash & cash equivalent TTM Growth	1.46 %	3.33 %	1.32 %	-2.61 %	-7.1 %

Quick ratio ranking by company, industry and sector >> Back to URGN Financial Strength Comparisons >> Go to Compare URGN Quick Ratio to its Competitors

News about Urogen Pharma Ltd Quick Ratio

UroGen Pharma Advances Bladder Cancer Fight with Milestone Phase 3 Trial Enrollment Amid Industry Challenges,

UroGen Pharma Reaches Major Milestone in Fight Against Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., July 07, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biotech company focused on developing innovative treatments for urothelial and specialty cancers, has announced a significant milestone in its endeavor to revolutionize cancer treatment. The company completed patient enrollment for its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a cutting-edge formulation designed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Advancements in Bladder Cancer TreatmentThe completion of enrollment in the UTOPIA clinical trial marks a pivotal moment for UroGen. The trial seeks to address a critical medical need in the management of LG-IR-NMIBC, a cancer known for its high recurrence rate and potential for progression. UGN-103 offers a promising therapeutic option that could transform the treatment landscape for patients grappling with this challenging condition.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $74.03 millions, cumulative Quick Ratio decreased to 2 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Urogen Pharma Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3732 to 3810.

Explain Quick Ratio?
How much Cash & cash equivalents URGN�s has?
What are URGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 432
Healthcare Sector	# 881
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
14.2	4.59	1.48
(Mar 31 2019)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions
Harmony Biosciences Holdings inc	3.02	$ 771.138 Millions	$ 254.981 Millions
Phio Pharmaceuticals Corp	2.96	$ 10.609 Millions	$ 3.583 Millions
Zevra Therapeutics Inc	2.95	$ 122.148 Millions	$ 41.369 Millions
Pyxis Oncology Inc	2.79	$ 55.572 Millions	$ 19.942 Millions
Zenas Biopharma Inc	2.78	$ 177.778 Millions	$ 64.043 Millions
Ptc Therapeutics inc	2.74	$ 2,127.918 Millions	$ 776.076 Millions
Beone Medicines Ltd	2.67	$ 5,955.905 Millions	$ 2,233.923 Millions
Biohaven Ltd	2.57	$ 161.125 Millions	$ 62.767 Millions
Ironwood Pharmaceuticals inc	2.49	$ 86.376 Millions	$ 34.733 Millions
Opko Health Inc	2.37	$ 384.036 Millions	$ 162.356 Millions
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions
Schrodinger Inc	2.20	$ 366.358 Millions	$ 166.292 Millions
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Corcept Therapeutics Inc	2.09	$ 370.703 Millions	$ 177.675 Millions
Dianthus Therapeutics Inc	1.95	$ 55.686 Millions	$ 28.515 Millions
Xeris Biopharma Holdings Inc	1.95	$ 262.164 Millions	$ 134.479 Millions
Ars Pharmaceuticals Inc	1.95	$ 138.354 Millions	$ 70.995 Millions
Lite Strategy Inc	1.92	$ 4.281 Millions	$ 2.234 Millions
Mineralys Therapeutics Inc	1.91	$ 101.273 Millions	$ 53.075 Millions
Amarin Corp Plcuk	1.85	$ 323.379 Millions	$ 175.136 Millions
Mustang Bio inc	1.80	$ 14.276 Millions	$ 7.947 Millions
Biovie Inc	1.78	$ 7.733 Millions	$ 4.350 Millions

Date modified: 2026-11-07T13:22:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.